Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.

@article{Fianchi2008GemtuzumabOC,
  title={Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia.},
  author={Luana Fianchi and Leonilde Pagano and Franco Leoni and Stefano Storti and Maria Teresa Voso and Caterina Giovanna Valentini and Sergio Rutella and Alessandra Scardocci and Morena Caira and Giacomo Gianfaldoni and Giuseppe Leone},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2008},
  volume={19 1},
  pages={128-34}
}
BACKGROUND Gemtuzumab ozogamicin (GO) is effective as single agent in the treatment of acute myeloid leukemia (AML). We evaluated efficacy and safety of a chemotherapy including growth factors, cytarabine, and GO (G-AraMy) in the treatment of poor-prognosis AML in elderly patients. PATIENTS AND METHODS In three Italian hematology departments from September 2003 to September 2006, 53 elderly patients [median age 69 years (range 65-77)] with untreated or primary refractory/relapsed AML were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Similar Papers

Loading similar papers…